Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

High and dysregulated secretion of epidermal growth factor from immune cells of patients with relapsing-remitting multiple sclerosis.
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin.
Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.
Development of nucleic acid drugs for neurological disorders.
JCV test stratifies PML risk in antibody-positive MS
Restless leg syndrome in different types of demyelinating neuropathies: a single-center pilot study.
Disc swelling and mild initial visual acuity loss predict a better short-term visual acuity outcome in bilateral acute optic neuritis.
[Prevention of multiple sclerosis: A realistic goal?]
The recurrent Guillain-Barré syndrome: a long-term population-based study.
Low dose naltrexone therapy in multiple sclerosis.
Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
Effects of early IL-17A neutralization on disease induction in a primate model of experimental autoimmune encephalomyelitis.
Placebo Cohorts in Phase-3 MS Treatment Trials - Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data.
Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis.
Enhancement of Membrane B7-H3 Costimulatory Molecule but Reduction of Its Soluble Form in Multiple Sclerosis.
Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
Historical Issues of Optic neuritis and Sensory Disorder in Persian Traditional Medicine.
The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
MARINOL®
Interferon β-1a therapy for multiple sclerosis during pregnancy: an unresolved issue.
Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations?
Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate
Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models.

Pages